CTL epitope analogs
We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.
1. A vaccine against human cytomogalovirus which comprises a peptide selected from the group consisting of SEQ ID NOs: 38, 52 and 64.
2. A vaccine of claim 1 which further comprises an adjuvant.
3. A vaccine of claim 2 wherein said adjuvant is a DNA adjuvant.
4. A vaccine of claim 3 , wherein said DNA adjuvant is a CpG DNA adjuvant.
5. An immunogenic composition for modifying the immune response of a mammal to human cytomegalovirus which comprises a peptide selected from the group consisting of SEQ ID Nos: 38, 52 and 64.
6. An immunogenic composition of claim 5 which further comprises an adjuvant.
7. An immunogenic composition of claim 6 wherein said adjuvant is a DNA adjuvant.
8. An immunogenic composition of claim 7 wherein said DNA adjuvant is a CpG DNA adjuvant.